Last updated: August 1, 2026
FLOXIN in Dextrose 5% is an intravenous formulation of ofloxacin, a racemic fluoroquinolone antibacterial supplied in 5% dextrose injection. The product has no meaningful remaining branded-exclusivity value in the United States. Its core compound and formulation rights expired long ago, the product is no longer a significant commercial franchise, and fluoroquinolone safety restrictions limit demand. Any investment case would depend on manufacturing, supply continuity, hospital contracting, or niche international distribution rather than patent ownership.
What is FLOXIN in Dextrose 5%?
FLOXIN in Dextrose 5% is an intravenous solution containing ofloxacin in a 5% dextrose vehicle. Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication. The formulation was used for susceptible bacterial infections when intravenous therapy was clinically appropriate.
| Attribute |
Product detail |
| Brand |
FLOXIN I.V. |
| Active ingredient |
Ofloxacin |
| Dosage form |
Intravenous solution |
| Vehicle |
5% dextrose |
| Drug class |
Fluoroquinolone antibacterial |
| Original sponsor |
Ortho-McNeil Pharmaceutical, associated with Johnson & Johnson |
| FDA status |
Discontinued branded product |
| Primary route |
Intravenous infusion |
| Current patent value |
None of commercial significance in the United States |
| Main competitors |
Generic ofloxacin, ciprofloxacin, levofloxacin and other hospital antibiotics |
FLOXIN I.V. was positioned as a parenteral version of the oral FLOXIN franchise. Ofloxacin was later displaced in many clinical settings by newer fluoroquinolones, including levofloxacin and moxifloxacin, as well as by non-fluoroquinolone hospital antibiotics.
What is the FDA and Orange Book status of FLOXIN in Dextrose 5%?
The commercial branded product is discontinued and is not an active growth asset in the U.S. pharmaceutical market. FDA product records distinguish between a product being discontinued for commercial reasons and a product being withdrawn for safety or efficacy concerns. FLOXIN I.V. was not removed from the market through a modern FDA safety withdrawal comparable to certain other fluoroquinolones.
The practical regulatory position is:
- No current branded launch opportunity exists for FLOXIN I.V.
- No remaining new-drug exclusivity protects the product.
- No commercially relevant Orange Book exclusivity remains.
- Any current U.S. product would need to rely on an approved generic or a new abbreviated or full application.
- FDA fluoroquinolone labeling restrictions reduce the addressable market.
The Orange Book remains the primary FDA source for identifying approved products, listed patents and regulatory exclusivities. A discontinued branded product does not create an active patent moat merely because its historical approval remains part of the FDA record (FDA, 2024a).
When does FLOXIN lose exclusivity?
FLOXIN lost meaningful U.S. exclusivity decades ago. Ofloxacin was an older fluoroquinolone whose basic compound protection expired well before the current pharmaceutical patent cycle.
The principal commercial conclusions are:
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Original compound patent |
Expired |
| Original formulation protection |
Expired or commercially irrelevant |
| Method-of-use exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial relevance |
| Orphan exclusivity |
Not applicable |
| Regulatory exclusivity today |
None |
The historical ofloxacin compound patent was associated with Daiichi-related research and was filed in the early 1980s. Any U.S. patent protection arising from that period expired no later than the early 2000s after accounting for the patent term applicable at the time. The patent estate therefore does not support a current branded-price strategy.
What patents protect FLOXIN in Dextrose 5%?
No active U.S. patent estate of commercial importance protects FLOXIN in Dextrose 5%.
Historical protection would have focused on:
- The ofloxacin chemical compound.
- Pharmaceutical compositions containing ofloxacin.
- Injectable solutions and stabilizing excipients.
- Methods of treating susceptible bacterial infections.
- Manufacturing processes for the active pharmaceutical ingredient.
Those categories are now largely exposed to generic competition. A new entrant could encounter ordinary regulatory and manufacturing requirements, but not a meaningful blocking patent position from the original FLOXIN franchise.
How strong is the patent estate for ofloxacin injection?
The patent estate is weak for investment purposes.
| Patent-estate factor |
Assessment |
| Compound patent |
Expired |
| Injectable formulation patent |
Expired or unenforceable against ordinary generic products |
| Method-of-use patents |
Expired |
| Manufacturing patents |
Potentially relevant only to a specific process |
| Patent-term restoration |
No material remaining value |
| Orange Book blocking position |
None of practical significance |
| Freedom-to-operate risk |
Low for standard ofloxacin injection, subject to product-specific review |
A manufacturer could still obtain process patents for a new crystallization process, impurity-control method, container system or manufacturing route. Those rights would protect a process or presentation, not the historical FLOXIN brand.
What formulation is protected by FLOXIN in Dextrose 5%?
The product’s formulation combines ofloxacin with 5% dextrose in an intravenous solution. Formulation characteristics include:
- A ready-to-use infusion presentation.
- Compatibility requirements for intravenous administration.
- Control of pH, osmolality, particulate matter and degradation products.
- Container and closure requirements.
- Sterility assurance and aseptic manufacturing.
- Stability over the labeled storage period.
These attributes can create technical barriers for a manufacturer, but they do not create durable exclusivity by themselves. A generic manufacturer can use a design-around formulation if it produces an equivalent approved product and satisfies FDA quality requirements.
The most relevant commercial barrier is sterile manufacturing capacity. Injectable products require validated aseptic processing, environmental controls, container-closure integrity testing and a reliable supply of active ingredient. These requirements can limit the number of suppliers even when patents have expired.
What generic entry risks exist for FLOXIN in Dextrose 5%?
Generic-entry risk is structurally high because ofloxacin is an old, off-patent small molecule. The principal risks are:
- Price erosion from generic injectable antibiotics.
- Hospital substitution through formulary protocols.
- Contracting pressure from group purchasing organizations.
- Limited clinical preference for ofloxacin over other fluoroquinolones.
- Supply interruptions caused by low-margin sterile manufacturing.
- Reduced use resulting from fluoroquinolone safety warnings.
- Therapeutic substitution with ciprofloxacin or levofloxacin.
Generic competition is not the only risk. The product may have limited direct generic competition because the market is small and manufacturers may prefer higher-volume injectables. That dynamic can preserve occasional pricing power during shortages, but it does not support durable franchise value.
What FDA safety restrictions affect FLOXIN demand?
FDA requires prominent fluoroquinolone warnings concerning disabling and potentially permanent adverse reactions involving tendons, muscles, joints, nerves and the central nervous system. Labeling also addresses risks such as peripheral neuropathy, QT prolongation, dysglycemia, aortic complications and exacerbation of myasthenia gravis.
FDA has advised that systemic fluoroquinolones should generally be reserved for certain uncomplicated infections when alternative treatments are available because the risks may outweigh benefits in those settings (FDA, 2018).
For an intravenous ofloxacin product, the clinical market is more defensible in serious infections involving susceptible organisms when alternatives are unsuitable. It is less attractive for routine empiric hospital use because physicians can select other agents with broader institutional support or more favorable contemporary guidelines.
How does FLOXIN compare with competing fluoroquinolones?
| Product |
Active ingredient |
Strategic position versus ofloxacin injection |
| FLOXIN I.V. |
Ofloxacin |
Legacy product with limited current commercial relevance |
| Cipro injection |
Ciprofloxacin |
Stronger historical hospital recognition and broader gram-negative positioning |
| Levaquin injection |
Levofloxacin |
More prominent respiratory and hospital use; widely generic |
| Avelox injection |
Moxifloxacin |
Stronger anaerobic and respiratory positioning, but also generic |
| Generic antibiotics |
Various |
Lower cost and formulary-driven substitution |
| Non-fluoroquinolone agents |
Various |
Increasingly important because of safety and resistance concerns |
Ofloxacin has a broad antibacterial spectrum but does not retain a clear contemporary advantage over ciprofloxacin or levofloxacin. The product’s primary disadvantages are its age, safety profile, resistance limitations and lack of a differentiated delivery system.
Which companies are challenging FLOXIN’s market position?
The competitive threat comes from generic manufacturers and alternative branded or generic antibiotics rather than from a single patent challenger. Potential competitors include manufacturers with sterile injectable capabilities such as:
- Fresenius Kabi
- Hikma Pharmaceuticals
- Sandoz
- Pfizer’s legacy Hospira operations
- Teva Pharmaceuticals
- Viatris
- Endo or legacy Par Pharmaceutical operations
- Regional injectable-drug manufacturers
The relevant competition is often determined by hospital contracts, shortage conditions, API access and manufacturing reliability. A company does not need to challenge a patent to displace FLOXIN. It can substitute another approved antibiotic through formulary management.
What Paragraph IV challenges affect FLOXIN?
No active, commercially relevant Paragraph IV campaign is associated with the historical FLOXIN I.V. franchise. Paragraph IV litigation would have been relevant when a generic applicant sought approval before expiration of listed patents. Those events are no longer central to the product because the original compound and formulation protections expired years ago.
The present regulatory pathway for a new ofloxacin injection would be an abbreviated new drug application, assuming the reference-product and product-specific requirements can be satisfied. The principal risks would concern bioequivalence, injectable-product quality, manufacturing controls and availability of an appropriate reference product, not patent litigation.
What patent litigation affects FLOXIN?
There is no current major U.S. patent litigation affecting FLOXIN in Dextrose 5%. Historical litigation involving ofloxacin-related patents would have limited current value because the relevant patents are expired.
A new commercial dispute could still arise over:
- False patent listing or Orange Book issues.
- Trade secrets relating to sterile manufacturing.
- Contract manufacturing terms.
- API specifications and impurity profiles.
- Trademark use of FLOXIN.
- Product liability and failure-to-warn claims.
- Distribution rights in foreign markets.
Those disputes would not restore exclusivity to the legacy product.
Are there biosimilar risks for FLOXIN?
Biosimilar risk is not applicable. Ofloxacin is a synthetic small-molecule drug, not a biologic. The relevant competitive pathways are generic drug approval, authorized generic distribution, therapeutic substitution and hospital procurement.
The distinction matters for valuation. A biosimilar faces complex biologic comparability requirements, while an ofloxacin injection competitor faces small-molecule pharmaceutical requirements. The regulatory barrier is lower than for a biologic, although sterile injectable manufacturing remains technically demanding.
Are there licensing deals for FLOXIN?
No current licensing structure creates identifiable strategic value for FLOXIN in Dextrose 5%. The historical product was associated with commercial rights held through the Ortho-McNeil and Johnson & Johnson pharmaceutical organization. Any legacy licensing or distribution arrangements would be commercially subordinate to the product’s discontinued status and expired exclusivity.
A new licensing opportunity could exist for:
- A regional injectable manufacturer.
- A hospital-focused distributor.
- A company with access to low-cost ofloxacin API.
- A supplier with a validated sterile filling line.
- An international market where ofloxacin injection remains registered.
Such a transaction would be a supply or distribution deal rather than a patent-backed licensing opportunity.
What is the revenue exposure from FLOXIN?
FLOXIN in Dextrose 5% does not represent a material current revenue driver for its historical sponsor. The product’s commercial value is constrained by:
- Product discontinuation.
- Generic availability.
- Low differentiation.
- Fluoroquinolone safety restrictions.
- Hospital substitution.
- Limited prescribing growth for legacy ofloxacin.
Revenue could still arise in selected international markets or during temporary shortages of alternative injectable antibiotics. That revenue would likely be volatile and dependent on procurement cycles. It should not be valued as recurring branded revenue without evidence of current sales, registration and supply contracts.
What manufacturing and intellectual-property barriers remain?
The key barriers are operational, not patent-based.
Manufacturing barriers
A supplier must manage:
- Sterile injectable production.
- Aseptic filling and validation.
- Container-closure integrity.
- Endotoxin and particulate limits.
- Stability testing.
- API impurity control.
- Cold-chain or controlled-storage requirements where applicable.
- FDA inspection readiness.
- Shortage reporting and supply continuity.
Intellectual-property barriers
Potential residual rights may include:
- A proprietary manufacturing process.
- A specialized container system.
- A private-label brand.
- Foreign-country formulation claims.
- Trade secrets concerning impurity reduction.
- Distribution agreements.
These rights would have narrow scope and would not prevent broad competition in standard ofloxacin injection.
What generic launch scenarios are plausible?
| Scenario |
Commercial outcome |
| No active U.S. supplier |
Limited sales during shortages, with substitution to other antibiotics |
| One approved supplier |
Temporary pricing power but high supply concentration |
| Several generic suppliers |
Rapid price erosion and low margin |
| International relaunch |
Moderate niche opportunity subject to local registration |
| New proprietary formulation |
Possible differentiation, but limited market size |
| Hospital-contract strategy |
Volume opportunity if supply reliability is superior |
The most credible investment thesis is a low-cost, reliable injectable supply platform rather than a FLOXIN brand revival. A relaunch would require a clear procurement gap, validated manufacturing capacity and a market where ofloxacin remains clinically accepted.
How strong is the investment case for FLOXIN in Dextrose 5%?
| Investment factor |
Assessment |
| Patent protection |
None of commercial significance |
| FDA exclusivity |
None |
| Brand recognition |
Historical, not growth-oriented |
| Clinical differentiation |
Weak |
| Generic risk |
High |
| Manufacturing complexity |
Moderate to high |
| Regulatory risk |
Moderate |
| Safety-related demand risk |
High |
| Revenue visibility |
Low |
| Licensing value |
Limited |
| Strategic value |
Possible only as a niche supply asset |
| Overall investment profile |
Low-value legacy product |
The product is unsuitable as a patent-driven investment. A potential transaction would require evidence of a supply shortage, a protected geographic market, a contracted customer base, or a differentiated formulation. Without those features, the economic value is likely limited to the manufacturing and distribution platform supporting the product.
Key Takeaways
- FLOXIN in Dextrose 5% is an intravenous ofloxacin product in a 5% dextrose vehicle.
- The original compound, formulation and method-of-use protections are expired.
- The branded product has no meaningful current U.S. exclusivity.
- No active Paragraph IV or major patent-litigation risk drives the market.
- Biosimilar analysis does not apply because ofloxacin is a small-molecule drug.
- Generic and therapeutic-substitution risk is high.
- FDA fluoroquinolone warnings constrain routine use.
- Sterile manufacturing and supply reliability are more important than patents.
- Current investment value would depend on niche international demand, shortage conditions or hospital supply contracts.
- The product is a weak standalone pharmaceutical asset and a potentially limited component of a generic injectable portfolio.
FAQs About FLOXIN in Dextrose 5%
Is FLOXIN in Dextrose 5% still marketed in the United States?
The historical branded product is discontinued and does not represent an active U.S. branded franchise. Any current availability would depend on an approved generic or a separately registered product.
Does FLOXIN in Dextrose 5% have an active patent?
No commercially meaningful U.S. patent protection remains for the legacy ofloxacin injectable product.
Can a company file an ANDA for ofloxacin injection?
A company may pursue an abbreviated pathway if it satisfies FDA requirements for the applicable reference product, equivalence, quality, labeling and sterile manufacturing controls.
Is ofloxacin injection exposed to biosimilar competition?
No. Ofloxacin is a synthetic small molecule. Competition occurs through generic drug pathways, not biosimilar applications.
Could FLOXIN be relaunched outside the United States?
A relaunch may be possible in selected foreign markets, subject to local registration, clinical acceptance, trademark rights, manufacturing compliance and commercial demand. The opportunity would be geographic and supply-driven rather than patent-driven.
References
- U.S. Food and Drug Administration. (2018). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024c). Discontinued drugs. https://www.fda.gov
- U.S. National Library of Medicine. (2024). Ofloxacin injection: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/
